NCT06961058 Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department
| NCT ID | NCT06961058 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Davis |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 528 participants |
| Start Date | 2025-06-03 |
| Primary Completion | 2029-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 528 participants in total. It began in 2025-06-03 with a primary completion date of 2029-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Main study objective: compare long-term buprenorphine treatment outcomes for patients who start buprenorphine for opioid use disorder (OUD) in the emergency department and are then referred to get outpatient buprenorphine treatment either via telehealth or at an in-person clinic. Researchers will: Compare rates of establishing outpatient OUD treatment, how long patients stay on buprenorphine, and patients' experience with care to determine whether patient experiences and outcomes are better for patients referred to telehealth treatment versus patients patients referred to in-person treatment after they leave the emergency department. Participants will: Be recruited from 3 different hospital emergency departments. Answer questionnaires at baseline and then 1, 3, 6, and 9 months after their initial emergency department visit.
Eligibility Criteria
Inclusion Criteria: * Adult patients who present to the emergency department and receive buprenorphine (either administered or prescribed) to treat OUD * do not have an established outpatient clinic where they will get buprenorphine when they leave the emergency department Exclusion Criteria: * inability to give consent * patients living in institutions (e.g., nursing homes, prisons) * unable to complete questionnaires in either English or Spanish
Contact & Investigator
Aimee Moulin, MD MAS
PRINCIPAL INVESTIGATOR
University of California, Davis
Frequently Asked Questions
Who can join the NCT06961058 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06961058 currently recruiting?
Yes, NCT06961058 is actively recruiting participants. Contact the research team at masoulsby@health.ucdavis.edu for enrollment information.
Where is the NCT06961058 trial being conducted?
This trial is being conducted at El Centro, United States, Sacramento, United States, Sylmar, United States.
Who is sponsoring the NCT06961058 clinical trial?
NCT06961058 is sponsored by University of California, Davis. The principal investigator is Aimee Moulin, MD MAS at University of California, Davis. The trial plans to enroll 528 participants.